Intra-Cellular Therapies, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.32 | -$0.32 | -$0.32 |
| Q2 2024 | 4 | -$0.19 | -$0.19 | -$0.19 |
| Q3 2024 | 11 | -$0.27 | -$0.07 | -$0.17 |
| Q4 2024 | 7 | -$0.10 | -$0.10 | -$0.10 |
| Q1 2025 | 5 | -$0.12 | -$0.12 | -$0.12 |
| Q2 2025 | 5 | -$0.03 | -$0.03 | -$0.03 |
| Q3 2025 | 6 | $0.12 | $0.12 | $0.12 |
| Q4 2025 | 9 | $0.29 | $0.29 | $0.29 |
Intra-Cellular Therapies, Inc. Earnings Date And Information
Intra-Cellular Therapies, Inc. last posted its earnings results on Wednesday, August 7th, 2024. The company reported $-0.16 earnings per share for the quarter, topping analysts' consensus estimates of $-0.18 by $0.02. The company had revenue of 161.39 M for the quarter and had revenue of 462.18 M for the year. Intra-Cellular Therapies, Inc. has generated $-1 earnings per share over the last year ($-1.46 diluted earnings per share) and currently has a price-to-earnings ratio of -90.02. Intra-Cellular Therapies, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, October 30th, 2024 based on prior year's report dates.
Intra-Cellular Therapies, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/07/2024 | Q2 2024 | -$0.18 | -$0.16 | 0.02 | $157.90 M | $161.39 M |
| 05/07/2024 | Q1 2024 | -$0.31 | -$0.16 | 0.15 | $144.87 M | |
| 02/22/2024 | Q4 2023 | -$0.44 | -$0.30 | 0.14 | $131.51 M | |
| 11/02/2023 | Q3 2023 | -$0.59 | -$0.25 | 0.34 | $119.25 M | $125.81 M |
| 08/03/2023 | Q2 2023 | -$0.62 | -$0.45 | 0.17 | $106.45 M | $110.13 M |
| 05/04/2023 | Q1 2023 | -$0.63 | -$0.46 | 0.17 | $94.73 M | |
| 03/01/2023 | Q4 2022 | -$0.62 | -$0.39 | 0.23 | $87.43 M | |
| 11/03/2022 | Q3 2022 | -$0.86 | -$0.57 | 0.29 | $65.99 M | $71.87 M |
| 08/09/2022 | Q2 2022 | -$0.79 | -$0.89 | -0.1 | $55.07 M | |
| 05/10/2022 | Q1 2022 | -$0.93 | -$0.78 | 0.15 | $34.76 M | |
| 03/01/2022 | Q4 2021 | -$1.05 | -$1.05 | 0 | $25.03 M | $25.52 M |
| 11/09/2021 | Q3 2021 | -$0.89 | -$0.95 | -0.06 | $22.08 M | $21.61 M |
| 08/09/2021 | Q2 2021 | -$0.79 | -$0.85 | -0.06 | $19.03 M | $19.01 M |
| 05/10/2021 | Q1 2021 | -$0.81 | -$0.65 | 0.16 | $15.58 M | |
| 02/25/2021 | Q4 2020 | -$0.85 | -$0.76 | 0.09 | $11.82 M | $12.40 M |
| 11/09/2020 | Q3 2020 | -$0.96 | -$0.79 | 0.17 | $5.53 M | $7.37 M |
| 08/10/2020 | Q2 2020 | -$0.94 | -$0.96 | -0.02 | $2.92 M | $1.88 M |
| 05/07/2020 | Q1 2020 | -$0.98 | -$0.73 | 0.25 | $882,516 | |
| 03/02/2020 | Q4 2019 | -$0.79 | -$0.73 | 0.06 | $60,613 | |
| 11/05/2019 | Q3 2019 | -$0.86 | -$0.63 | 0.23 | $12,500 | $0 |
Intra-Cellular Therapies, Inc. Earnings: Frequently Asked Questions
-
When is Intra-Cellular Therapies, Inc.'s earnings date?
Intra-Cellular Therapies, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, October 30th, 2024 based off last year's report dates.
-
Did Intra-Cellular Therapies, Inc. beat their earnings estimates last quarter?
In the previous quarter, Intra-Cellular Therapies, Inc. (:ITCI) reported $-0.16 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.18 by $0.02.
-
How can I listen to Intra-Cellular Therapies, Inc.'s earnings conference call?
The conference call for Intra-Cellular Therapies, Inc.'s latest earnings report can be listened to online.
-
How can I read Intra-Cellular Therapies, Inc.'s conference call transcript?
The conference call transcript for Intra-Cellular Therapies, Inc.'s latest earnings report can be read online.
-
How much revenue does Intra-Cellular Therapies, Inc. generate each year?
Intra-Cellular Therapies, Inc. (:ITCI) has a recorded annual revenue of $462.18 M.
-
How much profit does Intra-Cellular Therapies, Inc. generate each year?
Intra-Cellular Therapies, Inc. (:ITCI) has a recorded net income of $462.18 M. Intra-Cellular Therapies, Inc. has generated $-1.46 earnings per share over the last four quarters.
-
What is Intra-Cellular Therapies, Inc.'s price-to-earnings ratio?
Intra-Cellular Therapies, Inc. (:ITCI) has a price-to-earnings ratio of -90.02 and price/earnings-to-growth ratio is -1.94.
